Clinical effects of restarting antiplatelet therapy in patients with intracerebral hemorrhage

Antiplatelet medications have been used to treat ischemic stroke and cardiovascular diseases; however, patients with intracerebral hemorrhage (ICH) are at higher risk of re-bleeding.
Participants distinguished by early (≤30 days) and late (31–365 days after the index ICH) groups based on antiplatelet resumption had similar risk profiles for 1-year recurrent ICH (3.12% vs. 3.27%, respectively). All-cause mortality, major hemorrhagic and occlusive vascular events, and ischemic stroke were also similar between both groups at the 1-year follow-up.
According to the authors, starting antiplatelet therapy early is safe in patients with ICH.